Theravance Biopharma, Inc.
TBPH
$14.30
$0.130.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 77.21M | 65.27M | 64.38M | 63.19M | 62.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.21M | 65.27M | 64.38M | 63.19M | 62.02M |
| Cost of Revenue | 40.66M | 40.13M | 37.64M | 36.50M | 35.55M |
| Gross Profit | 36.54M | 25.14M | 26.74M | 26.69M | 26.47M |
| SG&A Expenses | 72.18M | 70.80M | 69.17M | 66.52M | 65.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.84M | 110.93M | 106.82M | 103.03M | 101.34M |
| Operating Income | -35.63M | -45.66M | -42.44M | -39.83M | -39.32M |
| Income Before Tax | 40.08M | -48.35M | -44.61M | -40.69M | -38.22M |
| Income Tax Expenses | 27.05M | 9.98M | 11.80M | 8.71M | 7.43M |
| Earnings from Continuing Operations | 13.03 | -58.33 | -56.42 | -49.40 | -45.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.03M | -58.33M | -56.42M | -49.40M | -45.65M |
| EBIT | -35.63M | -45.66M | -42.44M | -39.83M | -39.32M |
| EBITDA | -33.96M | -43.97M | -40.73M | -38.15M | -37.64M |
| EPS Basic | 0.25 | -1.19 | -1.15 | -1.01 | -0.92 |
| Normalized Basic EPS | 0.51 | -0.56 | -0.51 | -0.47 | -0.45 |
| EPS Diluted | 0.23 | -1.19 | -1.16 | -1.01 | -0.92 |
| Normalized Diluted EPS | 0.50 | -0.56 | -0.51 | -0.47 | -0.45 |
| Average Basic Shares Outstanding | 198.23M | 196.80M | 195.37M | 195.48M | 198.81M |
| Average Diluted Shares Outstanding | 198.78M | 196.80M | 195.37M | 195.48M | 198.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |